RenovoRx

RenovoRx RenovoRx (Nasdaq: RNXT) is developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device.

“The findings from this PK/PD study provide additional meaningful mechanistic support for our TAMP™ platform’s targeted ...
08/25/2026

“The findings from this PK/PD study provide additional meaningful mechanistic support for our TAMP™ platform’s targeted drug-delivery approach,” said Ramtin Agah, M.D., Executive Chairman, Chief Medical Officer, and Founder of RenovoRx. Learn about the PK/PD data from a sub-study of the ongoing Phase III TIGeR-PaC clinical trial published in the journal Cancer Chemotherapy and Pharmacology: https://bit.ly/3UDL7Zb

RenovoRx announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing P...
08/25/2026

RenovoRx announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC trial (NCT03257033) in Cancer Chemotherapy and Pharmacology. The study showed an approximately 51% tumor-site drug extraction, decreased systemic exposure, and a significant correlation between drug metabolite levels and tumor marker reduction, supporting the targeted drug-delivery approach of RenovoRx’s proprietary TAMP™ platform in locally advanced pancreatic cancer (LAPC). Learn more: https://bit.ly/3UDL7Zb

A recent Channel 8 News KLKN TV Lincoln feature highlights the clinical adoption of RenovoRx's RenovoCath® device at UNM...
08/24/2026

A recent Channel 8 News KLKN TV Lincoln feature highlights the clinical adoption of RenovoRx's RenovoCath® device at UNMC's Fred and Pamela Buffett Cancer Center at Nebraska Medicine, marking the first use of the device in the state.

The story includes insights from Ramtin Agah, MD, RenovoRx Founder and Chief Medical Officer, and Dr. Kelsey Klute, GI oncologist at Nebraska Medicine, on how the TAMP™ platform is delivers chemotherapy directly near the tumor site while potentially reducing the systemic side effects associated with intravenous chemotherapy.

Watch the full story: https://bit.ly/4hSFBLT

RenovoCath is FDA-cleared for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of LAPC in an ongoing clinical trial conducted under an IND.

RenovoRx announced that it has received written notification from The Nasdaq Stock Market LLC confirming that the Compan...
08/21/2026

RenovoRx announced that it has received written notification from The Nasdaq Stock Market LLC confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. For more information: https://bit.ly/4xWXvC4

RenovoRx's recently issued notice of allowance from the U.S. Patent and Trademark Office strengthens RenovoRx’s expandin...
08/20/2026

RenovoRx's recently issued notice of allowance from the U.S. Patent and Trademark Office strengthens RenovoRx’s expanding intellectual property portfolio and provides additional patent protection for RenovoCath®, an advanced dual-occlusion catheter, designed to deliver cancer therapies directly to targeted tumor sites, further supporting the Company’s commercialization strategy in precision oncology. For details: https://bit.ly/4grS4nD

RenovoRx announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the Company’s patent a...
08/20/2026

RenovoRx announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the Company’s patent application (U.S. Application No. 18/184,620) titled “Methods and Apparatuses for Delivery of Therapeutic Materials for the Treatment of Cancer.”

This patent will strengthen RenovoRx’s growing U.S. intellectual property portfolio, reinforcing the Company’s differentiated approach to targeted, local drug-delivery, and broadening protection for its TAMP™ (Trans-Arterial Micro-Perfusion) platform and RenovoCath® device. RenovoRx’s global intellectual property portfolio now includes 20 issued or allowed patents and 13 pending patents. Learn more: https://bit.ly/4grS4nD

Replay now available! Our CEO, Shaun Bagai, joined oncology KOLs Dae Won Kim, MD, of Moffitt Cancer Center and Ravi Shri...
08/19/2026

Replay now available! Our CEO, Shaun Bagai, joined oncology KOLs Dae Won Kim, MD, of Moffitt Cancer Center and Ravi Shridhar, MD, PhD, of AdventHealth Cancer Institute to discuss RenovoRx’s innovative Trans-Arterial Micro-Perfusion (TAMP™) targeted drug delivery platform and its potential role in advancing cancer care.

The discussion also highlighted real-world physician experience with TAMP, growing clinical adoption across cancer centers, the market opportunity for RenovoCath®, and the potential to expand the platform beyond pancreatic cancer.

Watch now: https://bit.ly/4h9CT4p

Ravi Shridhar, MD, PhD, of AdventHealth Cancer Institute, discussed how he has integrated RenovoRx's Trans-Arterial Micr...
08/18/2026

Ravi Shridhar, MD, PhD, of AdventHealth Cancer Institute, discussed how he has integrated RenovoRx's Trans-Arterial Micro-Perfusion (TAMP™) platform into his practice and what he believes is driving demand across both patients and physicians. Watch a replay of the Jones Trading webinar here: https://bit.ly/4h9CT4p

RenovoRx reached key milestones with its second quarter 2026 results, including completion of enrollment in the Phase II...
08/14/2026

RenovoRx reached key milestones with its second quarter 2026 results, including completion of enrollment in the Phase III TIGeR-PaC trial, positioning the majority of trial sites to transition to commercial use in the second half of the year. Strong first half performance prompted us to raise and tighten our full year revenue guidance. We believe RenovoRx is building a durable, capital-efficient commercial business. Management estimates that quarterly revenue of approximately $5 million would support cash-flow break-even, which our current plan targets for the fourth quarter of 2027.

Listen to a replay of our Q2 2026 financial results and business highlights conference call for more: https://bit.ly/4i8jMrN

"We ended the second quarter with 21 active commercial cancer center customers, an increase of more than 30% from the 16...
08/13/2026

"We ended the second quarter with 21 active commercial cancer center customers, an increase of more than 30% from the 16 centers reported at the time of our first quarter earnings call, and expanded our total commercial pipeline to 63 centers, including 42 additional centers progressing through evaluation, approval, and activation," said Shaun Bagai, Chief Executive Officer of RenovoRx.

For the first time, treatment is being delivered with RenovoCath® in a patient with sarcoma, marking expansion of the device to other solid tumors. Learn more: https://bit.ly/45XxYfW

Address

Mountain View, CA

Website

Alerts

Be the first to know and let us send you an email when RenovoRx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to RenovoRx:

Shortcuts

Share

Category